N
asopharyngeal carcinoma (NPC) is a unique malignancy that is particularly prevalent among the southern Chinese but is rare elsewhere. Numerous molecular alterations have been detected in this cancer (1) . Allelic loss of chromosome 14 and alterations in chromosome copy numbers are found commonly in NPC (1-3) as well as in a wide variety of other cancers (4) (5) (6) (7) . Alterations in chromosome 14 also have been reported in both early-onset colon cancers (8) and meningioma progression (9) . Hypermethylation and down-regulation of chromosome 14 genes are observed in glioblastomas (10) and oligodendroglial tumors (11) . These findings suggest that potential tumor suppressor genes (TSGs) mapping to chromosome 14 have a role in tumorigenesis. Deletion mapping of gastrointestinal (12) , bladder (13) , and ovarian (14) tumors identified chromosome 14 loci associated with tumor suppression at 14q11.1-q12, 14q12-13, 14q23-24.3, and 14q32.1-q32.2. In our previous NPC study, 2 critical regions (CRs) at 14q11.2-13.1 and 14q32.1 also were identified as being associated with growth suppression. Although CRs presumably harboring candidate TSGs have been identified, no candidate TSGs mapping to chromosome 14 have been identified as yet in NPC. Thus, further investigation of the role of chromosome 14 in NPC tumorigenesis is warranted. It is also of particular interest to us that chromosome 14 loss is associated with cancer metastasis in breast tumors (15) and with poor clinical prognosis for other head and neck cancers (16) . Thus, it is possible that a chromosome 14 TSG may be a useful prognostic marker in NPC.
In this study, we obtained functional evidence showing definitively that chromosome 14 is tumor suppressive in NPC. We used a microcellmedicated chromosome transfer (MMCT) approach to investigate whether intact chromosome 14 can functionally complement existing defects in an NPC cell line. CRs and candidate genes were identified. A presumptive TSG is up-regulated in microcell hybrids (MCHs) and down-regulated in tumor revertants arising after a long period of selection in vivo (17) . A candidate TSG, Mirror-Image POLydactyly 1 (MIPOL1), was identified in this study. MIPOL1 was first mapped in a patient with a genetic disease resulting in mirror-image polydactyly of hands and feet (18) and mild craniofacial and acallosal central nervous system midline defects (19) . Of perhaps only incidental interest is a recent transcriptome screening study identifying the insertion of the DGKB and neighboring ETV1 genes into the MIPOL1 gene, resulting in up-regulation of the ETV1 oncogene in prostate cancer (20) . To date, however, the function of MIPOL1 is still unknown. This study links this gene, associated with a developmental disorder, to cancer. We investigated its clinical relevance, cytolocalization, possible mechanisms of inactivation, and its ability to suppress tumor formation in vivo.
Results
Transfer of Intact Chromosome 14 Suppresses HONE1 Tumor Formation. The MMCT approach was used to transfer an intact human chromosome 14 into the tumorigenic NPC cell line, HONE1, using donor MCH-D14-C2. Microsatellite typing and whole-chromosome FISH were used to confirm the successful transfer of chromosome 14 into all 5 MCH cell lines (Fig. 1A and supporting information (SI) Fig. S1 ). Fig. 1B shows representative results from the microsatellite analysis.
The recipient HONE1 cell line is highly tumorigenic in nude mice, with palpable tumors consistently formed within 21 days and reaching a size greater than 900 mm 3 by 6 weeks after injection ( Fig. 1C and Table S1 ). The 5 MCHs suppress tumor growth in vivo, and only small tumors were observed 6 weeks after injection. (Fig. 1 A) . We re-injected 3 TSs, MCH-NPC-14E-TS10, -14T-TS2, and -14U-TS1, in mice to investigate their tumorigenicity; they were 100% tumorigenic and displayed higher tumor growth kinetics than their matched MCHs (Fig. 1C) , perhaps reflecting their in vivo selection in mice.
Based on the microsatellite typing and BAC FISH results, the MIPOL1 gene (36.737-37.090 Mb) located in CR2 between markers D14S75 and D14S286 that showed the highest loss (up to 73%) in the TSs ( Fig. 1 A and Fig. S2 ) was chosen for further study. BAC FISH with probes RP11-460G19 (36.831-37.010 Mb), which overlaps with MIPOL1, and with RP11-1116E12 (38.087-38.242 Mb), which is adjacent to the MIPOL1 region, showed 6 copies of the region where MIPOL1 maps in MCH-NPC-14T. Selective loss of 1 copy was observed with FISH analysis for both BACs in its TS, namely MCH-NPC-14T-TS2 (Fig. S2) . These findings are consistent with the loss of MIPOL1 and the nearby CR in the TS being associated with a subsequent increased tumorigenicity but do not exclude the possibility that other regional genes may be involved.
MIPOL1 Gene and Protein Expression Levels in MCHs, TSs, and NPC Cell
Lines and Patient Tumors. Up-regulation of MIPOL1 at both protein and mRNA levels was observed in the MCHs when compared with HONE1 cells, and extensive down-regulation of MIPOL1 was observed in the corresponding TSs ( Fig. 2 A and C) . MIPOL1 also was down-regulated in all 7 NPC cell lines when compared with a nontumorigenic immortalized normal nasopharyngeal epithelial cell line, NP69 ( Fig. 2 B and C) . The possible clinical relevance of MIPOL1 was investigated in 60 patient tumors: 38 (63%) showed down-regulation of MIPOL1 mRNA levels when compared with the corresponding nontumor tissues (Fig. 2D ).
Nuclear Localization of MIPOL1 Protein. By immunofluorescence staining, MIPOL1 protein was observed predominantly in the nucleus, and only a small fraction was observed in the cytoplasm of the NP69 cells (Fig. S3) . The MIPOL1 transfectant, MIPOL1-C16, was established using a previously described tetracycline-regulated vector, pETE-Bsd, and the genetically engineered HONE1-2 cell line (21) . When the MIPOL1 gene was switched on in the absence of doxycycline (dox), MIPOL1 protein localized mainly to the nucleus, as observed by immunofluorescence staining (Fig. S3 ). This nuclear localization also was seen in tissue sections of nonkeratinizing undifferen- tiated carcinoma (NPC) and normal epithelium using antibody specific for MIPOL1 (Fig. S4) . No significant cytoplasmic staining was seen, and the adjacent stroma was negative.
Silencing MIPOL1 Gene Expression by Promoter Hypermethylation and
Loss of Heterozygosity. Bisulfite genomic sequencing (BGS) showed a high frequency of methylation of 12 CpG sites in the MIPOL1 promoter in NPC cell lines HONE1 and HK1 but not in the immortalized normal nasopharyngeal epilithelial cell line NP69 (Fig. 3A) . Using methylation-specific PCR (MSP) primers located within those 12 CpG sites, we also observed methylated alleles in 6 NPC cell lines. In contrast, NP69 and CNE1 had only the unmethylated allele (Fig. 3B ). The chromosome 14 microcell donor, MCH-D14-C2, which shows only the unmethylated allele, was used as a control. Promoter hypermethylation was observed in 3 MIPOL1 down-regulated NPC tissues, T53, T62, and T68, when compared with their corresponding normal tissues, whereas T71 showed only the unmethylated allele (Fig. 3B ). This finding suggests promoter hypermethylation is an important mechanism for silencing MIPOL1 expression. With the use of the demethylation reagent, 5-aza-2Јdeoxycytidine, restoration of MIPOL1 expression was observed in all NPC cell lines by quantitative RT-PCR (Q-PCR), with the exception of the CNE1 cell line, in which only the unmethylated allele was observed. These results further confirm the role of promoter hypermethylation in NPC (Fig. 3C) .
In CNE1, microsatellite typing detected a continuous region of homozygosity for 6 markers spanning a 11.9-Mb region from D14S1040 to D14S288 (Fig. 3D ). NP69 and HONE1, in contrast, showed heterozygous patterns for 10 of 12 markers. These results are consistent with the loss of 1 copy of that particular region in CNE1. Three available pairs of MIPOL1 down-regulated NPC patient biopsies (T71, T81, and T82) (Fig. 2D ) and showed high loss of heterozygosity (LOH) in CR2 in tumor tissues. Thus, both promoter hypermethylation and LOH are likely to be important mechanisms for silencing MIPOL1 expression in both cell lines as well as in primary tumors.
To rule out the possibility of global methylation changes in the 14q region where MIPOL1 maps and to verify that the frequent downregulation and promoter hypermethylation of MIPOL1 is unique in CR2, the gene expression and the methylation status of 2 neighboring genes, SLC25A21 (36.219-36.711 Mb) and FOXA1 (37.128-37.134 Mb), were studied. No consistent change in SLC25A21 and FOXA1 expression was observed in the 5 MCH and TS pairs (Fig. S5A ). In addition, gene expression analysis shows that SLC25A21 was downregulated in only 2 of 7 NPC cell lines (CNE1 and C666-1), in contrast to MIPOL1, which was down-regulated in all these cell lines. HK1 was the only cell line showing down-regulated FOXA1 expression (Fig.  S5B ). SLC25A21 and FOXA1 showed methylation in the SLC25A21 promoter only in C666-1 cells, which displayed decreased SLC25A21 expression (Fig. S5C) . Taken together, the 2 genes mapping near MIPOL1 did not show frequent down-regulated gene expression or promoter hypermethylation in NPC cell lines, in contrast to MIPOL1. This finding provides further evidence of the importance of the MI-POL1 gene, mapping to CR2, in NPC tumorigenesis.
MIPOL1 Suppresses Tumor Growth in Vivo.
The previously described tetracycline-regulated gene expression system (21) was used to establish stable MIPOL1-expressing clones. MIPOL1-C1, MIPOL1-C12, MI-POL1-C16, and MIPOL1-C19 which show MIPOL1 over-expression, were selected for further studies after Q-PCR and Western blot screening (Fig. 4 A and B) . In the absence of dox, the gene expression in this inducible system is switched on; all 4 MIPOL1 transfectant clones show up-regulation of MIPOL1 when compared with the blasticidin (BSD)-C5 control. Their gene and protein expression levels are similar to or higher than those in the NP69 control. In the presence of dox, the gene expression levels of MIPOL1 are reduced significantly.
In the in vivo tumorigenicity assay, large tumors formed in all 6 sites injected with the vector-alone control, BSD-C5 (Ϯdox) within 14 to 21 days (Fig. 4C and Table S2 ). All 4 independent MIPOL1-expressing clones (Ϫdox) suppress tumor formation when MIPOL1 is expressed. When MIPOL1 expression is switched off with dox, the tumorigenicity is similar to that of BSD-C5 control. The differences in tumor growth kinetics between MIPOL1-expressing clones, vector-alone control, and their corresponding ϩdox controls are statistically significant (P Ͻ 0.05) (Table S2) . (Table S3 ). This observation was T2  T3  T4  T5  T6  T10  T11  T12  T13  T14  T17  T18  T19  T20  T21  T22  T23  T24  T26  T27  T31  T33  T40  T42  T46  T47  T48  T49  T50  T53  T54  T55  T56  T57  T58  T59  T60  T61  T62  T63  T64  T65  T66  T67  T68  T69  T70  T71  T72  T73  T74  T75  T76  T77  T78  T79  T80  T81  T82 Fold differences
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Fold differences C   14F  14F  -TS2  14M  14M  -TS2  14T  14T  -TS2  14U  14U  -TS1   HONE1  HK1  HNE1  CNE1  CNE2  C666- validated by microarray analysis of the current MIPOL1 stable transfectants versus the vector alone in the presence or absence of dox to regulate MIPOL1 gene expression in those stable clones (Table S3) . There is up-regulation of p21(WAF1/CIP1) and p27(KIP1) genes when MIPOL1 expression is induced. Because these 2 genes were among the top candidates differentially expressed in the microarray analysis, their relationships with MIPOL1 were investigated further by studying their gene and protein expression levels in the MIPOL1-stable clones. Over-expression of MIPOL1 is associated with increased expression of both p21(WAF1/CIP1) and p27(KIP1), when compared with the vectoralone control. p21(WAF1/CIP1) and p27(KIP1) expression levels return to those of vector-alone control when the gene is shut off (Fig. 4 A and  B) . These results are consistent with MIPOL1 expression correlating with p21(WAF1/CIP1) and p27(KIP1) expression.
To study further the tumor-suppressive mechanism of MIPOL1, the cell cycle status of MIPOL1-C12 and -C16 and BSD-C5 was studied. When MIPOL1 is expressed in MIPOL1-C12 and -C16 (Ϫdox), there are significant increases in the relative numbers of cells in G 0 /G 1 phase, from 54.9% to 70.0% and 68.5% (P Ͻ 0.05), respectively. In the presence of dox, there is no significant change in the number of cells in G 0 /G 1 phase among BSD-C5, MIPOL1-C12, and MIPOL1-C16 cell lines (53.5%, 57.7%, and 57.8%, respectively). These results suggest expression of MIPOL1 can induce G 0 /G 1 cell cycle arrest in the stable transfectants (Fig. 4D ).
Discussion
In this study, we provide functional evidence in NPC that transfer of an intact exogenous chromosome 14 suppresses tumor growth in vivo and that TSs exhibit tumorigenicity only after nonrandom elimination of CRs. Re-injection of the TSs into nude mice further confirms that the elimination of those CRs is critically related to the emergence of tumors. Interestingly, the TSs show higher tumor growth rates than the original HONE1 cell line. This phenomenon also was observed in 1 chromosome 14 TS derived from a tumor-suppressive esophageal carcinoma MCH (22) and presumably results from the selection in mice for aggressively growing cells capable of tumor formation in the mouse. Our previous MMCT studies showed that the transfer of chromosomes 9 and 17 into the same HONE1 cell line does not result in tumor suppression (23) , suggesting that the tumor-suppressive effects of chromosome 14 in NPC are chromosome specific.
The MIPOL1 gene located within CR2 was identified as a candidate TSG in NPC. Down-regulation of MIPOL1 mRNA in NPC cell lines and patient biopsies further confirms the importance of MIPOL1 in NPC development. Nuclear localization of MIPOL1 was demonstrated by both immunofluorescence and immunohistochemical staining. Immunohistochemical staining did not reveal a significant downregulation of MIPOL1 protein in the tumor versus normal epithelial cells. However, this method is not particularly quantitative. By contrast, Q-PCR is more sensitive for examining differences in expression between tumor and nontumor tissues.
Both promoter hypermethylation and allelic loss play a role in silencing MIPOL1 expression in NPC cell lines and tumor tissues. Low frequencies of down-regulation and promoter hypermethylation in 2 nearby genes, SLC25A21 and FOXA1, suggest the inactivation of MIPOL1 is unique and that there are no global methylation changes to the 2 neighboring genes mapping to this region in NPC.
A tetracycline-regulated inducible system was used to eliminate the effects of clonal variation. The same clones (Ϯdox) are used together for analysis, and only the transgene expression levels vary.
with the untreated cell lines. (D) We used 12 microsatellite markers for LOH study of 3 cell lines (HONE1, CNE1, and NP69) and 3 NPC patient biopsies (T71, 81, and 82). The MIPOL1 promoter is unmethylated in the CNE1 cell line. We investigated 3 NPC tissues showing down-regulation of MIPOL1. NP69 was used as control. The presence (white circles), absence (black circles), not determined (gray circles), homozygous pattern (black circles with ''1'' in the center), and heterozygous pattern (gray circles with ''2'' in the center) status of markers are as indicated. shows tumor-suppressive activity in the HONE1 cells. The nuclear localization of the MIPOL1 protein in the stable transfectant, NP69, and nontumor epithelium suggests that the function of MIPOL1 protein expression in the stable clones is similar to that in the NP69 condition. All 4 independent clones induce tumor suppression in the in vivo assay only when the gene is expressed, not when the gene expression is shut down. Our results provide strong evidence that MIPOL1 is tumor suppressive in NPC. The low protein expression levels of MIPOL1 observed in HONE1 cells suggest that MIPOL1 may belong to the class of genes that predispose to cancer through haploinsufficiency in the hemizygous state and therefore may not need a second mutation in the remaining wild-type allele in tumors (24, 25) . The expression level of MIPOL1 gene in the stable transfectant MIPOL1-C19 (ϩdox) further confirms this hypothesis. Its leaky expression results in MIPOL1 levels that are higher than in the vector alone but lower than in NP69. Expression higher than the level observed in the leaky clone is tumor suppressing.
Over-expression of MIPOL1 protein induces G 0 /G 1 cell cycle arrest and up-regulation of 2 negative regulators of G1 progression, the well-studied TSGs, p21(WAF1/CIP1) and p27(KIP1). These results are consistent with the tumor-suppressive effect of MIPOL1 being involved in these 2 common TSG pathways. Down-regulation of p21(WAF1/ CIP1) and p27(KIP1) correlates with more aggressive prostate cancer (26) . Loss of expression of p27(KIP1) was correlated with local recurrence in NPC (27, 28) . Our results add support to the notion that the functional role of MIPOL1 in NPC suppression is associated with the induction of expression of p21(WAF1/CIP1) and p27(KIP1), proteins that are associated with suppression of tumor growth in vivo. Further studies are required to investigate the actual functional role of MIPOL1 in the p21(WAF1/CIP1) and p27(KIP1) TSG pathways.
In conclusion, these studies provide clear evidence that the intact chromosome 14 suppresses tumor growth in NPC. A candidate TSG, MIPOL1, was identified and appears to play an essential role in NPC development. Our evidence suggests MIPOL1 is a candidate TSG. This interesting but little-studied gene of unknown function is well conserved in evolution and is associated with a developmental disorder resulting in polydactyly. Importantly, our studies now provide evidence that MIPOL1 expression also is associated with cancer.
Materials and Methods
Cell Culture. The donor cell line MCH-D14-C2, which contains an intact human chromosome 14 tagged with a neomycin resistance gene, MCH, TS, 7 NPC cell lines (HONE1, HK1, HNE1, CNE1, CNE2, C666 -1, and SUNE1), a tetracycline transactivator-producing cell line (HONE1-2), and an immortalized nasopharyngeal epithelial cell line (NP69) were cultured as previously described (21, 29 -32 ). In the current study, each of the MCHs injected into nude mice exhibited a delayed latency period before tumor formation; these tumors subsequently were excised and reconstituted into tissue culture to establish the TS cell lines used in the subsequent assays. Three TSs, MCH-NPC-14E-TS10, -14T-TS2, and -14U-TS1, were cultured for 4 to 8 weeks before being re-injected into nude mice.
NPC Tissue Specimens.
Matched normal nasopharyngeal and NPC biopsies from 60 NPC patients were collected from Queen Mary Hospital from 2006 to 2008, as previously described (33) . Approval for this study was obtained from the Hospital Institutional Review Board at the University of Hong Kong. Fiberoptic nasopharyngoscopy was used to obtain the paired normal and tumor biopsy materials. Tumor tissues were obtained directly from the site of tumor growth. If tumors were localized to 1 side, the normal tissue samples were taken from the contralateral side having a normal mucosal appearance and no evidence of contact bleeding. For patients who had bilateral tumor involvement, normal tissues were taken from the nasal cavity.
Microcell-Mediated Chromosome Transfer. The microcell donor, MCH-D14-C2, was used to transfer intact chromosome 14 into HONE1 cell lines as described (30, 34) . MCHs were obtained after 3 to 4 weeks' selection.
Whole-Chromosome and BAC FISH Analysis. The whole chromosome 14 probe, WCP 14 SpectrumGreen TM (Vysis) and BAC clones RP11-460G19 and RP11-116E12 (Invitrogen) were used for FISH analysis, as previously described (35, 36) . 
